Scienture Launches REZENOPY™, Highest-Dose Naloxone Spray, with Initial Orders Fulfilled
SCNX sits 85% above its 52-week low of $0.238 on light trading volume (0.1× avg).
Summary
Scienture has commercially launched REZENOPY™, the highest-dose FDA-approved naloxone nasal spray, and fulfilled initial purchase orders to U.S. wholesalers. The launch is backed by a dedicated national sales force targeting hospitals, EMS, pharmacies, and public health agencies. Payer coverage now reaches over 100 million lives, and GPO agreements provide access to more than 5,000 facilities—over 60% of the institutional naloxone market. This is the company's second FDA-approved commercial product, entering a $143 million U.S. naloxone market. The launch follows earlier patent grants and formulary wins, marking a critical step in revenue generation for a company that recently disclosed going concern doubts.
At the time of this announcement, SCNX was trading at $0.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.6M. The 52-week trading range was $0.24 to $2.60. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.